Negaban (temocillin)
/ Eumedica
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
114
Go to page
1
2
3
4
5
June 22, 2025
Role of S155, D159 and R214 Amino-Acid Residues in the Active Site of OXA-48 Variants
(ASM Microbe 2025)
- "All S155 A, K, D and T substitutions display a drastic reduction in carbapenem and temocillin hydrolytic activity of OXA-48, except for S155M...Our work further illustrates the remarkable propensity of OXA-48-like carbapenemases to evolve through mutations at positions outside the β5-β6 loop, but interacting with key residues of it. Our result further support the role of the salt bridge between R214 and D159, its stabilization by S155, to maintain the conformation and network of water molecules in the active site."
May 25, 2025
SCREENING CONUNDRUM AFTER UNEXPECTED POSTOPERATIVE IDENTIFICATION OF BLAOXA-48-LIKE CARBAPENEMASE-PRODUCING E.COLI
(ESPID 2025)
- "Culture of CSF leakage from the wound, observed on day 6 post-op, yielded blaOXA-244 E.coli sensitive to meropenem and ertapenem but resistant to temocillin and piperacillin-tazobactam (PTZ)...The child was treated with a combination of intrathecal gentamicin, IV meropenem and ceftazidime-avibactam...Learning Points/Discussion BlaOXA-48-like organisms are notoriously difficult to detect on routine meropenem containing CPE screening agars. This incidence highlights diagnostic limitations in detecting OXA-48-like CPE organisms, the necessity of tailored protocols in high-risk settings and vigilant postoperative surveillance."
Infectious Disease
May 01, 2025
Assessment of Phenotypic Tools for Detection of OXA-48, KPC, and NDM in Klebsiella pneumoniae in Oman.
(PubMed, Diagnostics (Basel))
- " In total, 80 GeneXpert/PCR-confirmed (40 OXA-48 and 20 KPC and NDM each) and 37 whole-genome-sequenced (25 OXA-232 and 6 KPC-2, plus NDM-1 and NDM-5) K. pneumoniae were subjected to screening by temocillin (30 μg disk) (MAST Diagnostica, Germany) and D71C (MASTDISCS®)...With high sensitivity and specificity, ease of performance, short turnaround time, and low cost, we recommend the ICT format for routine diagnostic use. In resource-constrained centers, the OXA-48 disk test is an excellent alternative with high sensitivity and specificity."
Journal • Infectious Disease • Pneumonia
April 02, 2025
Newly developed antibiotics against multidrug-resistant and carbapenem-resistant Gram-negative bacteria: action and resistance mechanisms.
(PubMed, Arch Microbiol)
- "Porin modifications reduce the influx of antibiotics, whereas overexpression of efflux pumps, particularly those in the resistance-nodulation-cell division (RND) family, actively expels antibiotics from bacterial cells, significantly lowering intracellular drug concentrations and leading to treatment failure.This review examines the mechanisms of action, resistance profiles, and pharmacokinetic/pharmacodynamic characteristics of newly developed antibiotics designed to combat infections caused by MDR and carbapenem-resistant Gram-negative pathogens. The antibiotics discussed include ceftazidime-avibactam, imipenem-relebactam, ceftolozane-tazobactam, meropenem-vaborbactam, aztreonam-avibactam, delafloxacin, temocillin, plazomicin, cefiderocol, and eravacycline."
Journal • Review • Critical care • Infectious Disease
March 05, 2025
Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): a randomised, pragmatic trial
(ESCMID Global 2025)
- No abstract available
Clinical • Late-breaking abstract
February 04, 2025
Pharmacodynamic optimisation of temocillin treatment against CTX-M-15-producing K. pneumoniae isolates in a hollow-fiber infection model
(ESCMID Global 2025)
- No abstract available
PK/PD data • Infectious Disease • Pneumonia
February 04, 2025
Population pharmacokinetic/pharmacodynamic analysis of intravenous temocillin for the treatment of 3rd generation cephalosporin-resistant Escherichia coli bacteraemia (ASTARTE study)
(ESCMID Global 2025)
- No abstract available
Clinical • PK/PD data
February 04, 2025
Treatment failure rates do not differ according to temocillin MIC in the treatment of Enterobacterales blood stream infection: an observational study
(ESCMID Global 2025)
- No abstract available
Clinical • Observational data • Infectious Disease
February 04, 2025
Rapid detection of temocillin resistance in third-generation cephalosporin resistant Enterobacteriaceae
(ESCMID Global 2025)
- No abstract available
February 04, 2025
Temocillin efficacy and emergence of resistance in Enterobacter cloacae complex in a murine peritonitis model
(ESCMID Global 2025)
- No abstract available
Preclinical
February 04, 2025
Evaluation of meropenem, ertapenem and temocillin screening breakpoints in the EUCAST rapid antimicrobial susceptibility testing (RAST) for rapid detection of OXA-48-producing Klebsiella pneumoniae directly from positive blood cultures
(ESCMID Global 2025)
- No abstract available
Infectious Disease • Pneumonia
February 04, 2025
Performance of antibiotic susceptibility testing methods for novel beta-lactam/beta-lactamase inhibitors and temocillin in carbapenemase-producing Enterobacterales: a comparative study
(ESCMID Global 2025)
- No abstract available
March 07, 2025
Prevalence and risk factors of antibiotic resistance for urinary tract infections in patients presenting to a Belgian tertiary care emergency department: testing the national guidelines against the local setting.
(PubMed, Acta Clin Belg)
- "Overall, fosfomycin (29.2%) and nitrofurantoin (28.6%) showed the highest resistance rates. Ceftriaxone revealed lower resistance rates (13.1%) compared to ciprofloxacin (17.0%) and cefuroxime (18.4%)...However, overall, and especially in patients at risk for ESBL-producing bacteria, temocillin would be an even better choice in our setting. National microbiological data should be reviewed to support recommending temocillin as a first-line antibiotic in patients presenting with upper UTI."
Journal • Infectious Disease • Nephrology
February 23, 2025
Interspecies differences in Plasma Protein Binding of Beta-Lactam Antibiotics.
(PubMed, Int J Antimicrob Agents)
- "Significant variability in protein binding was observed among and between different species for the tested drugs. The study highlights substantial interspecies differences in the plasma protein binding of cefiderocol, ceftriaxone, and temocillin. Our findings indicate the need for careful consideration of species-specific PPB in the optimization of beta-lactam dosing and the development of new pharmaceuticals."
Journal
February 05, 2025
Preserving the antimicrobial arsenal: exploring alternatives to carbapenems in ESBL battles within the southeast of Ireland.
(PubMed, J Med Microbiol)
- "Temocillin (TMC), mecillinam (MEC), cefiderocol (FDC), amikacin and fosfomycin (FOS) displayed excellent activity against all ESBL-PE isolates tested, with susceptibility rates of≥85%. Ciprofloxacin and amoxicillin-clavulanic acid were the least efficacious agents, with susceptibility rates≤20%.Conclusions. TMC, MEC, FDC and FOS offer promising alternatives to carbapenems, demonstrating efficacy against ESBL-PE. The use of these agents not only broadens the therapeutic arsenal against ESBL-PE but also mitigates the potential for escalating carbapenem resistance, especially in regions where the incidence of carbapenem resistance is increasing."
Journal • Infectious Disease
January 23, 2025
Variable temocillin protein binding and pharmacokinetics in different clinical conditions: Implications for target attainment.
(PubMed, Br J Clin Pharmacol)
- "Our study underscores the significant variation in temocillin clearance and unbound fractions among different participant groups, challenging the efficacy of traditional 2 g q12h dosing. For patients with enhanced renal function and lower inflammation, continuous infusion emerges as a more effective strategy to achieve optimal target attainment."
Journal • PK/PD data • Infectious Disease • Inflammation • Nephrology • Septic Shock • CRP
December 30, 2024
Population pharmacokinetics and dosing simulations of temocillin in liver transplanted paediatric patients: a prospective, open-label, non-randomized study.
(PubMed, Clin Microbiol Infect)
- "Although adequate in many instances, the current dosing regimen is likely inadequate for patients with low body weight, high renal function, or bacteria with high MIC, emphasizing the need for patient-specific factors to be considered in dose selection. These data support the importance of paediatric pharmacokinetic studies to optimize drug dosing regimens."
Journal • PK/PD data • Hepatology • Infectious Disease • Pediatrics • Transplantation
December 23, 2024
Temocillin efficacy against AmpC β-lactamase-producing Enterobacterales: a relevant alternative to cefepime?
(PubMed, J Antimicrob Chemother)
- "Temocillin appears to be reliable for ABPE infections. Our data showed a high therapeutic success rate. Its high tolerability, narrow spectrum and ease of administration could make temocillin a relevant alternative to cefepime, the current standard for ABPE infection."
Journal • Infectious Disease • Nephrology
December 05, 2024
Dissemination of antibiotic-resistant bacteria associated with microplastics collected from Monastir and Mahdia coasts (Tunisia).
(PubMed, Microb Pathog)
- "A high level of antibiotic resistance was observed for Penicillin G (97.82%) and Temocillin (86.95%). S26 strain presented the highest multidrug resistance with a multiple antibiotic resistance (MAR) index of 0.71."
Journal • CAT
November 08, 2024
Pyrexia of unknown origin in a patient with long standing rheumatoid arthritis
(BSR-CBC 2024)
- "Treatment- 5-10 mg prednisolone since 1998, adalimumab 2010, rituximab 2013-2022...She had recurrent episodes of pyuria and was given several courses of antibiotics, including meropenem, temocillin, fluconazole, gentamicin...There was no sustained response to iv methylprednisolone and a course of filgotinib given for possible systemic RA symptoms.She developed a dry cough and shortness of breath...Ureaplasma and mycoplasma do not have a cell wall, thus making beta-lactam antibiotics and vancomycin ineffective...The collaboration was invaluable. A course of doxycycline may be considered as a relatively low risk approach while awaiting microbiological confirmation in such cases."
Clinical • Cough • Fibrosis • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Interstitial Cystitis • Nephrology • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Urology
November 16, 2024
Real-life use of temocillin in the treatment of bone and joint infections due to extended spectrum β-lactamase-producing Enterobacterales.
(PubMed, JAC Antimicrob Resist)
- "So far, this is the first report of BJI successfully treated with temocillin. This suggests that temocillin may be an alternative to treat BJI involving difficult-to-treat Enterobacterales when oral therapy is not available."
Journal • Infectious Disease • Inflammation • Pain • Pneumonia
October 18, 2024
Effectiveness of temocillin in treatment of non-urinary tract infections caused by ESBL-producing Enterobacterales and risk factors for failure.
(PubMed, JAC Antimicrob Resist)
- "During non-urinary tract infections, the main use of temocillin was for LRTIs and IAIs due to ESBL-producing E. coli and K. pneumoniae. The main risk factor for failure was initial severity of the disease."
Journal • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases
September 25, 2024
Genetic and biochemical characterization of OXA-1186, a novel OXA-198-type carbapenemase hydrolysing cephalosporins in Citrobacter freundii.
(PubMed, J Antimicrob Chemother)
- "Here, we described a novel carbapenemase, OXA-1186, identified in C. freundii. Unlike OXA-198, OXA-1186 is able to hydrolyse broad-spectrum cephalosporins. This carbapenemase was carried on a broad-spectrum IncP6 plasmid identified in other Citrobacter species and non-fermenters."
Journal
August 28, 2024
ASTARTÉ: Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins
(clinicaltrials.gov)
- P3 | N=334 | Recruiting | Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Trial completion date: Sep 2023 ➔ Dec 2025 | Trial primary completion date: Sep 2023 ➔ Mar 2025
Trial completion date • Trial primary completion date
August 16, 2024
KSA-1, a naturally-occurring Ambler class A extended-spectrum β-lactamase from the enterobacterial species Kosakonia sacchari.
(PubMed, J Glob Antimicrob Resist)
- "KSA-1 is a class A ESBL, distantly related to known ESBLs, with a high activity also temocillin. The blaKSA-1 gene can be considered as intrinsic in the species."
Journal • Infectious Disease
1 to 25
Of
114
Go to page
1
2
3
4
5